Nova Mentis Life Science

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Nova Mentis Life Science had revenue of €204.23k and net profit of -€626.98k

(EUR)	June 2026	YoY
Revenue	204.23k	-
Gross profit	80.6k	38,526.38%
Net profit	-626.98k	394.15%
EBITDA	-594.17k	487.55%

Fundamentals

Metric	Value
Market capitalization	€865.24k
Number of shares	62.51m
52-week high/low	€0.11 - €0.00914
Dividends	No
Beta	-0.80
P/E ratio	-1.96
PEG ratio	0.23
P/B ratio	3.67
P/S ratio	10.74

Company profile

Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.